AON
ENQUIRY
Indications
AON is clinically indicated for the management and prevention of nausea and vomiting across a spectrum of medical challenges:
Chemotherapy-Induced Nausea and Vomiting (CINV): Specifically indicated for patients undergoing highly or moderately emetogenic cancer treatments.
Post-Operative Nausea and Vomiting (PONV): Used to prevent and treat symptoms following general anesthesia and surgical procedures.
Radiotherapy-Induced Nausea: Management of emesis in patients receiving total body irradiation or localized abdominal radiotherapy.
Gastroenteritis-Related Vomiting: Targeted relief for acute vomiting associated with viral or bacterial stomach infections, especially when oral rehydration is difficult.
Drug-Induced Nausea: Management of nausea caused by various pharmaceutical agents, including certain antibiotics and opioid analgesics.
Cyclic Vomiting Syndrome: Used as a therapeutic intervention for recurring episodes of severe vomiting and lethargy.
Pediatric Emesis: Indicated for children requiring anti-emetic support during acute illness under strict medical supervision.
Chemotherapy-Induced Nausea and Vomiting (CINV): Specifically indicated for patients undergoing highly or moderately emetogenic cancer treatments.
Post-Operative Nausea and Vomiting (PONV): Used to prevent and treat symptoms following general anesthesia and surgical procedures.
Radiotherapy-Induced Nausea: Management of emesis in patients receiving total body irradiation or localized abdominal radiotherapy.
Gastroenteritis-Related Vomiting: Targeted relief for acute vomiting associated with viral or bacterial stomach infections, especially when oral rehydration is difficult.
Drug-Induced Nausea: Management of nausea caused by various pharmaceutical agents, including certain antibiotics and opioid analgesics.
Cyclic Vomiting Syndrome: Used as a therapeutic intervention for recurring episodes of severe vomiting and lethargy.
Pediatric Emesis: Indicated for children requiring anti-emetic support during acute illness under strict medical supervision.
Uses
The clinical utility of AON centers on its ability to stabilize the digestive system by muting the chemical triggers of emesis:
Prevents Nausea and Vomiting from Chemotherapy: By blocking 5-HT3 receptors in both the peripheral and central nervous systems, AON prevents the “acute” phase of vomiting that typically occurs within 24 hours of treatment.
Used in Post-Operative Nausea: It stabilizes the gastrointestinal tract following anesthesia, allowing patients to recover more comfortably and begin oral intake sooner.
Treats Nausea During Radiotherapy: AON prevents the serotonin release triggered by cellular damage during radiation, ensuring the patient can complete their treatment schedule.
Used in Gastroenteritis-Related Vomiting: It helps break the “vomiting cycle,” allowing the stomach to settle so that essential fluids and electrolytes can be retained.
Helps with Drug-Induced Nausea: It provides a protective layer for the stomach’s nerve endings, reducing the sensitivity to irritating medications.
Support of Nutritional Intake: By eliminating the sensation of nausea, AON allows patients to maintain their appetite and nutritional status during chronic illness.
Reduction of Dehydration Risk: By stopping active vomiting, it prevents the dangerous loss of fluids and electrolytes, reducing the need for intravenous (IV) rehydration.
Prevents Nausea and Vomiting from Chemotherapy: By blocking 5-HT3 receptors in both the peripheral and central nervous systems, AON prevents the “acute” phase of vomiting that typically occurs within 24 hours of treatment.
Used in Post-Operative Nausea: It stabilizes the gastrointestinal tract following anesthesia, allowing patients to recover more comfortably and begin oral intake sooner.
Treats Nausea During Radiotherapy: AON prevents the serotonin release triggered by cellular damage during radiation, ensuring the patient can complete their treatment schedule.
Used in Gastroenteritis-Related Vomiting: It helps break the “vomiting cycle,” allowing the stomach to settle so that essential fluids and electrolytes can be retained.
Helps with Drug-Induced Nausea: It provides a protective layer for the stomach’s nerve endings, reducing the sensitivity to irritating medications.
Support of Nutritional Intake: By eliminating the sensation of nausea, AON allows patients to maintain their appetite and nutritional status during chronic illness.
Reduction of Dehydration Risk: By stopping active vomiting, it prevents the dangerous loss of fluids and electrolytes, reducing the need for intravenous (IV) rehydration.
Dosage & Storage
Strict adherence to storage and dosage protocols ensures the molecular stability and efficacy of the Ondansetron formulation:
Standard Adult Dosage: The dosage is strictly determined by the clinical scenario. For chemotherapy, a common dose is 4 mg or 8 mg taken 30 minutes before the session starts.
Maintenance Dosing: Following the initial dose, a physician may prescribe subsequent doses every 8 to 12 hours for 1–2 days to prevent delayed nausea.
Storage Temperature: Store AON in a cool, dry environment where the temperature remains below 30°C.
Light and Moisture Protection: Keep the medication in its original blister packaging or Alu-Alu strip to prevent environmental degradation and loss of potency.
Pediatric Dosing: Dosage for children is strictly based on body weight or body surface area and must be calculated by a pediatrician.
Safety Protocol: Always store the medication in a secure location, well out of the reach of children and domestic pets.
Standard Adult Dosage: The dosage is strictly determined by the clinical scenario. For chemotherapy, a common dose is 4 mg or 8 mg taken 30 minutes before the session starts.
Maintenance Dosing: Following the initial dose, a physician may prescribe subsequent doses every 8 to 12 hours for 1–2 days to prevent delayed nausea.
Storage Temperature: Store AON in a cool, dry environment where the temperature remains below 30°C.
Light and Moisture Protection: Keep the medication in its original blister packaging or Alu-Alu strip to prevent environmental degradation and loss of potency.
Pediatric Dosing: Dosage for children is strictly based on body weight or body surface area and must be calculated by a pediatrician.
Safety Protocol: Always store the medication in a secure location, well out of the reach of children and domestic pets.
Directions For Use
To ensure that AON is absorbed efficiently and provides the intended relief, patients should follow these expert instructions:
Proactive Administration: For CINV and PONV, AON is most effective when taken before the trigger (e.g., 30–60 minutes before chemotherapy or surgery).
Administration with Food: AON can be taken with or without food. However, taking it with a small, light snack may help those with sensitive stomachs.
Swallow Whole: If using the tablet form, swallow it whole with a full glass of water.
Orally Disintegrating Forms: If using MD (Mouth Dissolving) tablets, allow the tablet to dissolve on the tongue without chewing, then swallow with saliva.
Consistent Timing: Maintain a regular schedule if multiple doses are prescribed to ensure a constant “anti-emetic shield” in the bloodstream.
Avoid Double Dosing: If a dose is missed, take it as soon as possible unless it is nearly time for the next dose. Do not take two doses at once.
Proactive Administration: For CINV and PONV, AON is most effective when taken before the trigger (e.g., 30–60 minutes before chemotherapy or surgery).
Administration with Food: AON can be taken with or without food. However, taking it with a small, light snack may help those with sensitive stomachs.
Swallow Whole: If using the tablet form, swallow it whole with a full glass of water.
Orally Disintegrating Forms: If using MD (Mouth Dissolving) tablets, allow the tablet to dissolve on the tongue without chewing, then swallow with saliva.
Consistent Timing: Maintain a regular schedule if multiple doses are prescribed to ensure a constant “anti-emetic shield” in the bloodstream.
Avoid Double Dosing: If a dose is missed, take it as soon as possible unless it is nearly time for the next dose. Do not take two doses at once.
Precautions
Before initiating therapy with AON, the following medical considerations and safeguards should be reviewed:
Cardiac History: Use with caution in patients with a history of heart rhythm disorders, specifically “QT prolongation.” A healthcare provider should be informed of any heart conditions.
Electrolyte Imbalance: Ensure that levels of potassium and magnesium are within the normal range, as imbalances can increase the risk of cardiac side effects.
Serotonin Syndrome: While rare, inform your doctor if you are taking SSRIs or SNRIs (antidepressants), as combining these with Ondansetron can affect serotonin levels.
Liver Function: Patients with severe hepatic impairment require dose adjustments, typically not exceeding a total of 8 mg per day.
Bowel Obstruction: If you have recently had abdominal surgery, inform your doctor, as AON can mask symptoms of a bowel obstruction due to its effect on gastric transit.
Pregnancy and Breastfeeding: AON should be used during pregnancy only if clearly needed and prescribed by a doctor, particularly in the first trimester.
Cardiac History: Use with caution in patients with a history of heart rhythm disorders, specifically “QT prolongation.” A healthcare provider should be informed of any heart conditions.
Electrolyte Imbalance: Ensure that levels of potassium and magnesium are within the normal range, as imbalances can increase the risk of cardiac side effects.
Serotonin Syndrome: While rare, inform your doctor if you are taking SSRIs or SNRIs (antidepressants), as combining these with Ondansetron can affect serotonin levels.
Liver Function: Patients with severe hepatic impairment require dose adjustments, typically not exceeding a total of 8 mg per day.
Bowel Obstruction: If you have recently had abdominal surgery, inform your doctor, as AON can mask symptoms of a bowel obstruction due to its effect on gastric transit.
Pregnancy and Breastfeeding: AON should be used during pregnancy only if clearly needed and prescribed by a doctor, particularly in the first trimester.
Side Effects
Headache
Constipation
Fatigue
Injection site reaction
Dizziness
Constipation
Fatigue
Injection site reaction
Dizziness
Medical Disclaimer
The information provided is for educational and informational purposes only and is not intended as medical advice.
Always consult a healthcare professional for medical advice, diagnosis, or treatment.
Agnes Life Sciences does not claim that any of its products can diagnose, treat, cure or prevent any disease.
This product is a prescription medication and should only be used under the guidance of a licensed medical practitioner.
Always consult a healthcare professional for medical advice, diagnosis, or treatment.
Agnes Life Sciences does not claim that any of its products can diagnose, treat, cure or prevent any disease.
This product is a prescription medication and should only be used under the guidance of a licensed medical practitioner.
Indications
AON is clinically indicated for the management and prevention of nausea and vomiting across a spectrum of medical challenges:
Chemotherapy-Induced Nausea and Vomiting (CINV): Specifically indicated for patients undergoing highly or moderately emetogenic cancer treatments.
Post-Operative Nausea and Vomiting (PONV): Used to prevent and treat symptoms following general anesthesia and surgical procedures.
Radiotherapy-Induced Nausea: Management of emesis in patients receiving total body irradiation or localized abdominal radiotherapy.
Gastroenteritis-Related Vomiting: Targeted relief for acute vomiting associated with viral or bacterial stomach infections, especially when oral rehydration is difficult.
Drug-Induced Nausea: Management of nausea caused by various pharmaceutical agents, including certain antibiotics and opioid analgesics.
Cyclic Vomiting Syndrome: Used as a therapeutic intervention for recurring episodes of severe vomiting and lethargy.
Pediatric Emesis: Indicated for children requiring anti-emetic support during acute illness under strict medical supervision.
Chemotherapy-Induced Nausea and Vomiting (CINV): Specifically indicated for patients undergoing highly or moderately emetogenic cancer treatments.
Post-Operative Nausea and Vomiting (PONV): Used to prevent and treat symptoms following general anesthesia and surgical procedures.
Radiotherapy-Induced Nausea: Management of emesis in patients receiving total body irradiation or localized abdominal radiotherapy.
Gastroenteritis-Related Vomiting: Targeted relief for acute vomiting associated with viral or bacterial stomach infections, especially when oral rehydration is difficult.
Drug-Induced Nausea: Management of nausea caused by various pharmaceutical agents, including certain antibiotics and opioid analgesics.
Cyclic Vomiting Syndrome: Used as a therapeutic intervention for recurring episodes of severe vomiting and lethargy.
Pediatric Emesis: Indicated for children requiring anti-emetic support during acute illness under strict medical supervision.
Uses
The clinical utility of AON centers on its ability to stabilize the digestive system by muting the chemical triggers of emesis:
Prevents Nausea and Vomiting from Chemotherapy: By blocking 5-HT3 receptors in both the peripheral and central nervous systems, AON prevents the “acute” phase of vomiting that typically occurs within 24 hours of treatment.
Used in Post-Operative Nausea: It stabilizes the gastrointestinal tract following anesthesia, allowing patients to recover more comfortably and begin oral intake sooner.
Treats Nausea During Radiotherapy: AON prevents the serotonin release triggered by cellular damage during radiation, ensuring the patient can complete their treatment schedule.
Used in Gastroenteritis-Related Vomiting: It helps break the “vomiting cycle,” allowing the stomach to settle so that essential fluids and electrolytes can be retained.
Helps with Drug-Induced Nausea: It provides a protective layer for the stomach’s nerve endings, reducing the sensitivity to irritating medications.
Support of Nutritional Intake: By eliminating the sensation of nausea, AON allows patients to maintain their appetite and nutritional status during chronic illness.
Reduction of Dehydration Risk: By stopping active vomiting, it prevents the dangerous loss of fluids and electrolytes, reducing the need for intravenous (IV) rehydration.
Prevents Nausea and Vomiting from Chemotherapy: By blocking 5-HT3 receptors in both the peripheral and central nervous systems, AON prevents the “acute” phase of vomiting that typically occurs within 24 hours of treatment.
Used in Post-Operative Nausea: It stabilizes the gastrointestinal tract following anesthesia, allowing patients to recover more comfortably and begin oral intake sooner.
Treats Nausea During Radiotherapy: AON prevents the serotonin release triggered by cellular damage during radiation, ensuring the patient can complete their treatment schedule.
Used in Gastroenteritis-Related Vomiting: It helps break the “vomiting cycle,” allowing the stomach to settle so that essential fluids and electrolytes can be retained.
Helps with Drug-Induced Nausea: It provides a protective layer for the stomach’s nerve endings, reducing the sensitivity to irritating medications.
Support of Nutritional Intake: By eliminating the sensation of nausea, AON allows patients to maintain their appetite and nutritional status during chronic illness.
Reduction of Dehydration Risk: By stopping active vomiting, it prevents the dangerous loss of fluids and electrolytes, reducing the need for intravenous (IV) rehydration.
Dosage & Storage
Strict adherence to storage and dosage protocols ensures the molecular stability and efficacy of the Ondansetron formulation:
Standard Adult Dosage: The dosage is strictly determined by the clinical scenario. For chemotherapy, a common dose is 4 mg or 8 mg taken 30 minutes before the session starts.
Maintenance Dosing: Following the initial dose, a physician may prescribe subsequent doses every 8 to 12 hours for 1–2 days to prevent delayed nausea.
Storage Temperature: Store AON in a cool, dry environment where the temperature remains below 30°C.
Light and Moisture Protection: Keep the medication in its original blister packaging or Alu-Alu strip to prevent environmental degradation and loss of potency.
Pediatric Dosing: Dosage for children is strictly based on body weight or body surface area and must be calculated by a pediatrician.
Safety Protocol: Always store the medication in a secure location, well out of the reach of children and domestic pets.
Standard Adult Dosage: The dosage is strictly determined by the clinical scenario. For chemotherapy, a common dose is 4 mg or 8 mg taken 30 minutes before the session starts.
Maintenance Dosing: Following the initial dose, a physician may prescribe subsequent doses every 8 to 12 hours for 1–2 days to prevent delayed nausea.
Storage Temperature: Store AON in a cool, dry environment where the temperature remains below 30°C.
Light and Moisture Protection: Keep the medication in its original blister packaging or Alu-Alu strip to prevent environmental degradation and loss of potency.
Pediatric Dosing: Dosage for children is strictly based on body weight or body surface area and must be calculated by a pediatrician.
Safety Protocol: Always store the medication in a secure location, well out of the reach of children and domestic pets.
Directions For Use
To ensure that AON is absorbed efficiently and provides the intended relief, patients should follow these expert instructions:
Proactive Administration: For CINV and PONV, AON is most effective when taken before the trigger (e.g., 30–60 minutes before chemotherapy or surgery).
Administration with Food: AON can be taken with or without food. However, taking it with a small, light snack may help those with sensitive stomachs.
Swallow Whole: If using the tablet form, swallow it whole with a full glass of water.
Orally Disintegrating Forms: If using MD (Mouth Dissolving) tablets, allow the tablet to dissolve on the tongue without chewing, then swallow with saliva.
Consistent Timing: Maintain a regular schedule if multiple doses are prescribed to ensure a constant “anti-emetic shield” in the bloodstream.
Avoid Double Dosing: If a dose is missed, take it as soon as possible unless it is nearly time for the next dose. Do not take two doses at once.
Proactive Administration: For CINV and PONV, AON is most effective when taken before the trigger (e.g., 30–60 minutes before chemotherapy or surgery).
Administration with Food: AON can be taken with or without food. However, taking it with a small, light snack may help those with sensitive stomachs.
Swallow Whole: If using the tablet form, swallow it whole with a full glass of water.
Orally Disintegrating Forms: If using MD (Mouth Dissolving) tablets, allow the tablet to dissolve on the tongue without chewing, then swallow with saliva.
Consistent Timing: Maintain a regular schedule if multiple doses are prescribed to ensure a constant “anti-emetic shield” in the bloodstream.
Avoid Double Dosing: If a dose is missed, take it as soon as possible unless it is nearly time for the next dose. Do not take two doses at once.
Precautions
Before initiating therapy with AON, the following medical considerations and safeguards should be reviewed:
Cardiac History: Use with caution in patients with a history of heart rhythm disorders, specifically “QT prolongation.” A healthcare provider should be informed of any heart conditions.
Electrolyte Imbalance: Ensure that levels of potassium and magnesium are within the normal range, as imbalances can increase the risk of cardiac side effects.
Serotonin Syndrome: While rare, inform your doctor if you are taking SSRIs or SNRIs (antidepressants), as combining these with Ondansetron can affect serotonin levels.
Liver Function: Patients with severe hepatic impairment require dose adjustments, typically not exceeding a total of 8 mg per day.
Bowel Obstruction: If you have recently had abdominal surgery, inform your doctor, as AON can mask symptoms of a bowel obstruction due to its effect on gastric transit.
Pregnancy and Breastfeeding: AON should be used during pregnancy only if clearly needed and prescribed by a doctor, particularly in the first trimester.
Cardiac History: Use with caution in patients with a history of heart rhythm disorders, specifically “QT prolongation.” A healthcare provider should be informed of any heart conditions.
Electrolyte Imbalance: Ensure that levels of potassium and magnesium are within the normal range, as imbalances can increase the risk of cardiac side effects.
Serotonin Syndrome: While rare, inform your doctor if you are taking SSRIs or SNRIs (antidepressants), as combining these with Ondansetron can affect serotonin levels.
Liver Function: Patients with severe hepatic impairment require dose adjustments, typically not exceeding a total of 8 mg per day.
Bowel Obstruction: If you have recently had abdominal surgery, inform your doctor, as AON can mask symptoms of a bowel obstruction due to its effect on gastric transit.
Pregnancy and Breastfeeding: AON should be used during pregnancy only if clearly needed and prescribed by a doctor, particularly in the first trimester.
Side Effects
Headache
Constipation
Fatigue
Injection site reaction
Dizziness
Constipation
Fatigue
Injection site reaction
Dizziness
Medical Disclaimer
The information provided is for educational and informational purposes only and is not intended as medical advice.
Always consult a healthcare professional for medical advice, diagnosis, or treatment.
Agnes Life Sciences does not claim that any of its products can diagnose, treat, cure or prevent any disease.
This product is a prescription medication and should only be used under the guidance of a licensed medical practitioner.
Always consult a healthcare professional for medical advice, diagnosis, or treatment.
Agnes Life Sciences does not claim that any of its products can diagnose, treat, cure or prevent any disease.
This product is a prescription medication and should only be used under the guidance of a licensed medical practitioner.
